TATVATatva Chintan Pharma Chem Limited
Chemicals · Specialty Chemicals · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Tatva Chintan Pharma Chem Limited engages in the manufacture and sale of specialty chemicals in India, Germany, the United States of America, China, Singapore, and internationally. It offers structure directing agents (SDAs); phase transfer catalysts (PTCs); electrolyte salts for super capacitor batteries; pharmaceutical and agrochemical intermediates, and other specialty chemicals (PASC); and brominated flame retardants. The company serves automotive, refinery, pharmaceutical, agrochemicals, paints and coatings, dyes and pigments, personal care, and flavors and fragrances sectors. Tatva Chintan Pharma Chem Limited was incorporated in 1996 and is headquartered in Vadodara, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on TATVA — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Revenue growth: 42.9% YoY
- • Profit growth: 140.5% YoY
- • Debt/Equity: 0.15
- • Price vs SMA200: above
- • Golden cross setup: SMA50 above SMA200
- • Supertrend: bullish
Bull case
- • Revenue growth: 42.9% YoY
- • Profit growth: 140.5% YoY
- • Debt/Equity: 0.15
- • Price vs SMA200: above
Bear case
- • ROE: 5.4%
- • ROCE: 6.2%
- • MACD: bearish
- • Price vs EMA21: below
Key risks
- • ROE: 5.4%
- • ROCE: 6.2%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹72.31). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.